LLY

993.68

-1.26%↓

JNJ

243.09

-0.47%↓

ABBV

226.6

-0.48%↓

NVS

155.61

-4.23%↓

AZN

193.4

-2.25%↓

LLY

993.68

-1.26%↓

JNJ

243.09

-0.47%↓

ABBV

226.6

-0.48%↓

NVS

155.61

-4.23%↓

AZN

193.4

-2.25%↓

LLY

993.68

-1.26%↓

JNJ

243.09

-0.47%↓

ABBV

226.6

-0.48%↓

NVS

155.61

-4.23%↓

AZN

193.4

-2.25%↓

LLY

993.68

-1.26%↓

JNJ

243.09

-0.47%↓

ABBV

226.6

-0.48%↓

NVS

155.61

-4.23%↓

AZN

193.4

-2.25%↓

LLY

993.68

-1.26%↓

JNJ

243.09

-0.47%↓

ABBV

226.6

-0.48%↓

NVS

155.61

-4.23%↓

AZN

193.4

-2.25%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

4.62 -3.35

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.54

Максимум

4.78

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+317.54% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	55M 444M
Предишно отваряне	7.97
Предишно затваряне	4.62

Настроения в новините

By Acuity

34%

66%

77 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2026 г., 20:38 ч. UTC

Печалби

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10.03.2026 г., 23:06 ч. UTC

Печалби

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10.03.2026 г., 22:51 ч. UTC

Значими събития в новините

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10.03.2026 г., 21:21 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10.03.2026 г., 21:15 ч. UTC

Печалби

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10.03.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10.03.2026 г., 21:14 ч. UTC

Печалби

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10.03.2026 г., 21:13 ч. UTC

Печалби

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q Rev $597.3M >FNV

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q EPS $1.90

10.03.2026 г., 20:57 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

10.03.2026 г., 20:44 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10.03.2026 г., 20:23 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:16 ч. UTC

Печалби

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10.03.2026 г., 20:13 ч. UTC

Печалби

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10.03.2026 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

317.54% нагоре

12-месечна прогноза

Среден 20 USD 317.54%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

77 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.